Statements (94)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
soluble guanylate cyclase stimulator
|
| gptkbp:approves |
gptkb:2013
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Adempas
|
| gptkbp:class |
vasodilator
|
| gptkbp:clinical_trial |
Phase III
Phase III trials long-term treatment Phase II trials improved exercise capacity reduced symptoms of pulmonary arterial hypertension |
| gptkbp:contraindication |
pregnancy
severe hypotension severe liver impairment severe hepatic impairment concurrent use of nitrates concomitant use of nitrates concomitant use with nitrates |
| gptkbp:developed_by |
gptkb:physicist
|
| gptkbp:dosage_form |
gptkb:tablet
tablets 1 mg tablet 2 mg tablet 0.5 mg tablet |
| gptkbp:duration |
as prescribed by physician
|
| gptkbp:education |
importance of adherence to therapy
recognizing side effects when to seek medical attention |
| gptkbp:effective_date |
2013-10-23
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
oral tablet
film-coated tablet |
| gptkbp:has_ability |
1 mg
0.5 mg 1.5 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Adempas
|
| gptkbp:indication |
chronic thromboembolic pulmonary hypertension
|
| gptkbp:ingredients |
gptkb:riociguat
|
| gptkbp:interacts_with |
gptkb:beer
antihypertensives CY P450 inducers CY P450 inhibitors |
| gptkbp:invention |
2027
patented 2028-05-01 |
| gptkbp:is_monitored_by |
blood pressure
liver function hemoglobin levels |
| gptkbp:is_used_for |
pulmonary arterial hypertension
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Boehringer_Ingelheim
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Europe gptkb:Australia gptkb:Japan gptkb:USA gptkb:United_States gptkb:Native_American_tribe gptkb:Adempas gptkb:riociguat over 50 countries |
| gptkbp:metabolism |
CY P3 A4
CY P1 A1 |
| gptkbp:part_of |
Bayer's cardiovascular portfolio
|
| gptkbp:pharmacokinetics |
bioavailability 73%
oral administration half-life 12 hours |
| gptkbp:population |
adults
children over 18 years |
| gptkbp:previous_name |
gptkb:battle
|
| gptkbp:price |
varies by region
|
| gptkbp:requires |
available online
|
| gptkbp:research_focus |
combination therapies
cost-effectiveness studies new indications long-term safety studies pediatric use studies |
| gptkbp:safety_features |
risk of bleeding
risk of hypotension not for use in patients with pulmonary veno-occlusive disease |
| gptkbp:side_effect |
dizziness
headache nausea vomiting diarrhea hypotension |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:bfsParent |
gptkb:Bayer_Health_Care
gptkb:Bayer_Pharmaceuticals |
| gptkbp:bfsLayer |
3
|